Economic burden of Alzheimer disease and managed care considerations.

  title={Economic burden of Alzheimer disease and managed care considerations.},
  author={Winston Wong},
  journal={The American journal of managed care},
  volume={26 8 Suppl},
  • W. Wong
  • Published 1 August 2020
  • Medicine
  • The American journal of managed care
Alzheimer disease is the most common cause of dementia and the fifth leading cause of death in adults older than 65 years. The estimated total healthcare costs for the treatment of Alzheimer disease in 2020 is estimated at $305 billion, with the cost expected to increase to more than $1 trillion as the population ages. Most of the direct costs of care for Alzheimer disease are attributed to skilled nursing care, home healthcare, and hospice care. Indirect costs of care, including quality of… 
Chronic Care, Dementia Care Management, and Financial Considerations.
Alzheimer’s Disease: Epidemiology and Clinical Progression
Results suggest that use of biomarkers alongside neurocognitive tests will become an important part of clinical practice as new disease-modifying therapies are introduced and NIA-AA stage 3 (subtle cognitive decline with AD biomarker positivity) could be useful in combination with other tools for treatment decision-making.
The economic imperatives for technology enabled wellness centered healthcare
This work explains how connected health technology can be integrated with conventional approaches and guide public health policy toward wellness-based care models and strategies to relieve the escalating economic burdens of managed care.
Cost‐effectiveness of aducanumab to prevent Alzheimer's disease progression at current list price
Aducanumab is not cost‐effective at the estimated price of $56,000 even under ideal circumstances in which it completely halts AD progression, despite being recently approved by the Food and Drug Administration despite the lack of clinical effectiveness data.
Clinical Staging of Alzheimer’s Disease: Concordance of Subjective and Objective Assessments in the Veteran’s Affairs Healthcare System
Higher concordance between clinician’s assessment and test-based assessment of Alzheimer's disease severity in dementia specialty clinics is found, indicating a critical need for improved understanding of clinical assessments and decision-making to identify appropriate patients for anti-amyloid therapy.
Genomics as a Clinical Decision Support Tool for Identifying and Addressing Modifiable Causes of Cognitive Decline and Improving Outcomes: Proof of Concept Support for This Personalized Medicine Strategy
Initial case reports are encouraging and lend support to the hypothesis of the benefit of a genomically targeted personalized medicine approach to improve outcomes in individuals with cognitive decline who are at high risk for Alzheimer’s.
Costs associated with treatment of insomnia in Alzheimer’s disease caregivers: a comparison of mindfulness meditation and cognitive behavioral therapy for insomnia
Treatment of insomnia with MAP-i, compared to CBT-I, yields substantial cost savings for society and the healthcare system and has critical implications for insomnia treatment dissemination and its benefits to AD caregivers and other community populations with insomnia.
Bilingualism and Aging: Implications for (Delaying) Neurocognitive Decline
The present article critically reviews neuroscientific evidence for another such factor, i.e., speaking multiple languages, and contextualize and stress the importance of the research program that seeks to uncover and understand potential connections between bilingual language experience and cognitive aging trajectories, inclusive of the socio-economic impact it can have.